Literature DB >> 19882751

Including receptor flexibility and induced fit effects into the design of MMP-2 inhibitors.

Jacob D Durrant1, César Augusto F de Oliveira, J Andrew McCammon.   

Abstract

Matrix metalloproteinases (MMPs) comprise a class of flexible proteins required for normal tissue remodeling. Overexpression of MMPs is associated with a wide range of pathophysiological processes, including vascular disease, multiple sclerosis, Alzheimer's disease, and cancer. Nearly all MMP inhibitors have failed in clinical trials, in part due to lack of specificity. Due to the highly dynamic molecular motions of the MMP-2 binding pockets, the rational drug design of MMP inhibitors has been very challenging. To address these challenges, in the current study we combine computer docking with molecular dynamics (MD) simulations in order to incorporate receptor-flexibility and induced-fit effects into the drug-design process. Our strategy identifies molecular fragments predicted to target multiple MMP-2 binding pockets. 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19882751      PMCID: PMC2950069          DOI: 10.1002/jmr.989

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  55 in total

1.  Dynamics of stromelysin/inhibitor interactions studied by 15N NMR relaxation measurements: comparison of ligand binding to the S1-S3 and S'1-S'3 subsites.

Authors:  P Yuan; V P Marshall; G L Petzold; R A Poorman; B J Stockman
Journal:  J Biomol NMR       Date:  1999-09       Impact factor: 2.835

Review 2.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Authors:  Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

3.  A new role for old ligands: discerning chelators for zinc metalloproteinases.

Authors:  Faith E Jacobsen; Jana A Lewis; Seth M Cohen
Journal:  J Am Chem Soc       Date:  2006-03-15       Impact factor: 15.419

Review 4.  Matrix metalloproteinase inhibitors.

Authors:  S M Wojtowicz-Praga; R B Dickson; M J Hawkins
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics.

Authors:  G Mautino; N Oliver; P Chanez; J Bousquet; F Capony
Journal:  Am J Respir Cell Mol Biol       Date:  1997-11       Impact factor: 6.914

Review 6.  Matrix metalloproteinases and metastasis.

Authors:  D E Kleiner; W G Stetler-Stevenson
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

7.  Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1.

Authors:  X Zhang; N C Gonnella; J Koehn; N Pathak; V Ganu; R Melton; D Parker; S I Hu; K Y Nam
Journal:  J Mol Biol       Date:  2000-08-11       Impact factor: 5.469

Review 8.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

9.  Similarity of binding sites of human matrix metalloproteinases.

Authors:  Viera Lukacova; Yufen Zhang; Martin Mackov; Peter Baricic; Soumyendu Raha; Jorge A Calvo; Stefan Balaz
Journal:  J Biol Chem       Date:  2004-01-19       Impact factor: 5.157

10.  An improved relaxed complex scheme for receptor flexibility in computer-aided drug design.

Authors:  Rommie E Amaro; Riccardo Baron; J Andrew McCammon
Journal:  J Comput Aided Mol Des       Date:  2008-01-15       Impact factor: 3.686

View more
  10 in total

1.  Molecular dynamics and docking simulations as a proof of high flexibility in E. coli FabH and its relevance for accurate inhibitor modeling.

Authors:  Yunierkis Pérez-Castillo; Matheus Froeyen; Miguel Angel Cabrera-Pérez; Ann Nowé
Journal:  J Comput Aided Mol Des       Date:  2011-04-23       Impact factor: 3.686

2.  Molecular recognition in the case of flexible targets.

Authors:  Anthony Ivetac; J Andrew McCammon
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

3.  Site-directed mutations of anti-amantadine scFv antibody by molecular dynamics simulation: prediction and validation.

Authors:  Sanlei Xie; Jianyi Wang; Xuezhi Yu; Tao Peng; Kai Yao; Sihan Wang; Demei Liang; Yuebin Ke; Zhanhui Wang; Haiyang Jiang
Journal:  J Mol Model       Date:  2020-02-04       Impact factor: 1.810

4.  Structural model of ligand-G protein-coupled receptor (GPCR) complex based on experimental double mutant cycle data: MT7 snake toxin bound to dimeric hM1 muscarinic receptor.

Authors:  Catherine Marquer; Carole Fruchart-Gaillard; Guillaume Letellier; Elodie Marcon; Gilles Mourier; Sophie Zinn-Justin; André Ménez; Denis Servent; Bernard Gilquin
Journal:  J Biol Chem       Date:  2011-06-17       Impact factor: 5.157

5.  MDA-9/syntenin is essential for factor VIIa-induced signaling, migration, and metastasis in melanoma cells.

Authors:  Hanaa Aissaoui; Célia Prévost; Ahmed Boucharaba; Kamel Sanhadji; Jean-Claude Bordet; Claude Négrier; Habib Boukerche
Journal:  J Biol Chem       Date:  2014-12-10       Impact factor: 5.157

6.  Modeling Structural Coordination and Ligand Binding in Zinc Proteins with a Polarizable Potential.

Authors:  Jiajing Zhang; Wei Yang; Jean-Philip Piquemal; Pengyu Ren
Journal:  J Chem Theory Comput       Date:  2012-01-02       Impact factor: 6.006

7.  Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach.

Authors:  Anthony Ivetac; J Andrew McCammon
Journal:  Chem Biol Drug Des       Date:  2010-07-05       Impact factor: 2.817

8.  POVME: an algorithm for measuring binding-pocket volumes.

Authors:  Jacob D Durrant; César Augusto F de Oliveira; J Andrew McCammon
Journal:  J Mol Graph Model       Date:  2010-11-03       Impact factor: 2.518

9.  An integrated computational approach to rationalize the activity of non-zinc-binding MMP-2 inhibitors.

Authors:  Antonella Di Pizio; Mariangela Agamennone; Massimiliano Aschi
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

10.  Interleukin-6 increases matrix metalloproteinase-14 (MMP-14) levels via down-regulation of p53 to drive cancer progression.

Authors:  Jillian M Cathcart; Anna Banach; Alice Liu; Jun Chen; Michael Goligorsky; Jian Cao
Journal:  Oncotarget       Date:  2016-09-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.